Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LTI 291

Next Previous
Drug Profile

LTI 291

Alternative Names: BIA 28-6156/LTI-291; LTI-00291; LTI-291

Latest Information Update: 17 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lysosomal Therapeutics
  • Developer BIAL; Lysosomal Therapeutics
  • Class Amides; Antiparkinsonians; Cyclohexanes; Ethers; Pyrazoles; Pyrimidines; Small molecules
  • Mechanism of Action Glucosylceramidase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Parkinson's disease

Most Recent Events

  • 13 Apr 2026 BIAL initiates an expanded-access programme for Parkinson disease in USA, Italy, Portugal, Spain, UK (NCT07522606)
  • 15 Oct 2025 Chemical structure information added.
  • 25 Aug 2025 Phase-I clinical trials in Parkinson's disease in Hungary (PO) (CTIS2025-520754-11-00)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top